

Haematologica  
HAEMATOL/2019/242289  
Version 3

Individualized dosing guidelines for PEGasparaginase and factors  
influencing the clearance: a population pharmacokinetic model

Robin Q.H. Kloos, Ron Mathôt, Rob Pieters, and Inge M. van der Sluis

Disclosures: Robin Kloos declares that she has no conflict of interest. Authors Rob Pieters and I.M. van der Sluis received research support and consultancy fees from Jazz Pharmaceuticals and Medac. Author Ron Mathôt has received travel grants from Shire and Bayer.

Contributions: Author R. Kloos has collected the data, performed the analysis, interpreted the data and written the manuscript. Author R. Mathôt has performed the analysis, interpreted the data and written the manuscript. Authors R. Pieters and I.M. van der Sluis have designed the research, interpreted the data and written the manuscript.